Neurology: Volume 97, Number 21, November 23, 2021 Exam #2 - Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy

About this course

  • Released: 11/23/2021
  • Expires: 11/23/2024

DEFINING SPEECH SUBTYPES IN DE NOVO PARKINSON DISEASE: RESPONSE TO LONG-TERM LEVODOPA THERAPY

LEARNING OBJECTIVES:

Upon completion of the article by Rusz et al, the participant should be able to:

  • Discuss how the presence of imprecise pronunciation of consonants was associated with other clinical assessments of patients with Parkinson disease (PD) in this study
  • Describe how demographics and patient-/disease-related factors differed between clusters of patients with PD with various speech phenotypes identified in this study
  • Describe how specific speech-related functions worsened in patients with PD not treated with levodopa, compared with treated patients, in this study

CORE COMPETENCIES:

The article by Rusz et al covers the following core competency:
  • Medical Knowledge

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm) have no disclosures.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME